Leerink Partnrs Upgrades AbCellera Biologics (NASDAQ:ABCL) to Strong-Buy

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) was upgraded by equities research analysts at Leerink Partnrs to a "strong-buy" rating in a research note issued to investors on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for AbCellera Biologics' Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.64) EPS and FY2026 earnings at ($0.28) EPS.

A number of other research firms also recently commented on ABCL. KeyCorp increased their target price on shares of AbCellera Biologics from $4.00 to $5.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Leerink Partners began coverage on shares of AbCellera Biologics in a research report on Monday. They issued an "outperform" rating and a $5.00 target price on the stock. Finally, Truist Financial dropped their target price on shares of AbCellera Biologics from $28.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $7.50.

AbCellera Biologics Stock Performance

Shares of NASDAQ:ABCL traded up $0.33 during trading hours on Monday, reaching $4.22. The stock had a trading volume of 6,979,281 shares, compared to its average volume of 3,462,229. AbCellera Biologics has a 1 year low of $1.89 and a 1 year high of $4.29. The firm's 50 day moving average is $2.72 and its 200-day moving average is $2.74. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -7.54 and a beta of 0.62.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02. The company had revenue of $4.24 million for the quarter, compared to the consensus estimate of $7.12 million. AbCellera Biologics had a negative net margin of 737.56% and a negative return on equity of 15.98%. Analysts forecast that AbCellera Biologics will post -0.59 EPS for the current year.

Institutional Trading of AbCellera Biologics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Stratos Wealth Advisors LLC purchased a new stake in shares of AbCellera Biologics in the first quarter valued at about $27,000. DKM Wealth Management Inc. purchased a new stake in shares of AbCellera Biologics in the fourth quarter valued at about $29,000. Janney Montgomery Scott LLC purchased a new stake in shares of AbCellera Biologics in the first quarter valued at about $29,000. AssuredPartners Investment Advisors LLC purchased a new stake in shares of AbCellera Biologics in the first quarter valued at about $34,000. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of AbCellera Biologics in the fourth quarter valued at about $40,000. Hedge funds and other institutional investors own 61.42% of the company's stock.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.